ClinicalTrials.gg
Active, not recruitingNCT02843035LEAPUpdated Jul 10, 2026

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

A Phase 2 interventional study of venglustat (GZ402671) and imiglucerase in Gaucher Disease Type 1 and Gaucher Disease Type 3, sponsored by Genzyme, a Sanofi Company. Active, not recruiting at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Gaucher Disease by Sanofi — 2 open to participants now, 4 under way, 2 of them phase 3. Gaucher Disease · Sanofi.

Enrollment
15th of 19
12 · median 26
Started
2017
the only one that year
Phase 2
2 of 24
none open now
Registered
13th of 24
by date

Among the 24 studies in Gaucher Disease by Sanofi, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2017, is one of 2 in phase 2, and was the 13th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

2 of the 24 studies in Gaucher Disease by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Gaucher Disease by Sanofi, or all of them as a file.
02

Study summary

Part 1: Biomarker evaluation/screening phase

Primary Objectives:

  • Evaluate cerebrospinal fluid (CSF) biomarkers in adult Gaucher disease Type 3 (GD3) participants that distinguish GD3 from adult Gaucher disease Type 1 (GD1) participants
  • Screen adult GD3 participants who qualify for treatment with venglustat in Parts 2, Part 3, and Part 4 Parts 2 and 3: Combination treatment phases

Primary objectives:

  • Evaluate short-term (Part 2) and long-term (Part 3) safety and tolerability of venglustat in combination with Cerezyme in adult GD3 participants
  • Evaluate the change in CSF central nervous system (CNS) biomarkers (glucosylceramide [GL-1] and lyso-glucosylceramide [lyso-GL-1]) from adult GD3 participants receiving venglustat in combination with Cerezyme (Part 2 only) Part 4: Extended treatment phase with monotherapy

Primary objectives:

  • Evaluate safety and tolerability of venglustat monotherapy in adult GD3 participants who have remained systemically stable on venglustat in combination with Cerezyme Parts 2 and 3: Combination treatment phases

Secondary Objectives:

  • Evaluate the pharmacokinetics (PK) of venglustat in adult GD3 participants
  • Evaluate the efficacy of venglustat in combination with Cerezyme in systemic disease in adult GD3 participants by assessing spleen volume, liver volume, hemoglobin level and platelet count
  • Evaluate the efficacy of venglustat in combination with Cerezyme on neurological function in adult GD3 participants by assessing Ataxia using the Scale for the Assessment and Rating of Ataxia (SARA)
  • Evaluate plasma biomarkers (lyso-GL-1 and GL-1) in adult GD3 participants Part 4: Extended treatment phase with monotherapy

Secondary objectives:

  • Evaluate the efficacy of venglustat in systemic disease in adult GD3 participants by assessing spleen volume, liver volume, hemoglobin level and platelet count
  • Evaluate the efficacy of venglustat on neurological function in adult GD3 participants by assessing Ataxia using the Scale for the Assessment and Rating of Ataxia (SARA)
  • Evaluate plasma biomarkers (lyso-GL-1 and GL-1) in adult GD3 participants
Read the detailed description

The total duration for GD1 participants is 45 days (Part 1), while for GD3 participants the total duration is up to approximately 10 years

03

Conditions studied

  • Gaucher Disease Type 1
  • Gaucher Disease Type 3

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

GD3 and GD1 participants must meet the following criteria to be eligible for this study:

  • GD1 participant is ≥18 and ≤40 years of age.
  • GD3 participant is ≥18 years of age.
  • Participant must provide written prior to any study-related procedures being performed.
  • Participant has a clinical diagnosis of Gaucher disease Type 1 (GD1) or Gaucher disease Type 3 (GD3) and documented deficiency of acid beta-glucosidase activity confirming this diagnosis.
  • Participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months and is within the therapeutic goals defined below, and is deemed clinically stable for at least 1 year by the Investigator.
  • Participant has reached Gaucher disease therapeutic goals defined as all of the following to be eligible for this study:

    • level of ≥11.0 g/dL for females and ≥12.0 g/dL for males.
    • count ≥100,000/mm3.
    • Spleen volume \<10 multiples of normal (MN), or total splenectomy (provided the splenectomy occurred >3 years prior to randomization).
    • Liver volume \<1.5 MN.
    • No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening.
  • Participant has maintained GD therapeutic goals defined as all of the following to be eligible for entering Part 4 of this study:

    • Hemoglobin level of ≥11.0 g/dL for females and ≥12.0 g/dL for males
    • Platelet count ≥100 000/mm3
    • Spleen volume \<10 multiples of normal (MN), or total splenectomy
    • Liver volume \<1.5 MN
    • No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to entering Part 4
  • Participant, if female and of , must have a negative pregnancy test [urine beta-human chorionic gonadotropin (β-hCG)] at baseline.
  • If participant has a history of seizures, except for myoclonic seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of cytochrome P450 (CYP) 3A.
  • Participant is willing to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for 72 hours prior to administration of the first dose of venglustat and for the duration of the treatment period.
  • Oculomotor apraxia characterized by a horizontal saccade abnormality.
  • Female participants of childbearing potential and male participants must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use 2 acceptable effective methods of for the duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of venglustat.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Substrate reduction therapy or chaperone therapy for GD within 6 months prior to enrollment.
  • Participant has had a partial or total splenectomy within 3 years prior to randomization.
  • Participant is blood transfusion-dependent.
  • Prior esophageal varices or liver infarction or current liver enzymes ( [ALT]/ aspartate aminotransferase [AST]) or total >2 times the , unless the participant has a diagnosis of Gilbert Syndrome.
  • Participant has any disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation.
  • Participant has renal insufficiency, as defined by an estimated \<30 mL/min/1.73m2 at the screening visit.
  • Participant has received an product within 30 days prior to enrollment.
  • Participant has a history of cancer, with the exception of basal cell carcinoma.
  • Participant has myoclonic seizures.
  • Participant is pregnant or lactating.
  • Participant has, according to World Health Organization (WHO) Grading, a cortical cataract > one-quarter of the lens circumference (Grade cortical cataract-2) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2). Participants with nuclear cataracts will not be excluded.
  • Participant requires use of invasive ventilatory support.
  • Participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily.
  • Participant is unable to receive treatment with Cerezyme due to a known or is unwilling to receive Cerezyme treatment to ensure maintenance of Gaucher treatment goals.
  • Participant is currently receiving potentially cataractogenic medications (, psoralens used in dermatology with ultraviolet light therapy [PUVA], typical antipsychotics, and glaucoma medications) or any medication that may worsen the vision of a participant with cataract (eg, alphaadrenergic glaucoma medications).
  • Participant has received strong or moderate inducers or inhibitors of within 15 days or 5 half-lives from screening, whichever is longer, prior to enrolment in Part 2. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration in Parts 2 and 3.
  • Participant is scheduled for in-patient hospitalization including elective surgery, during the study.
  • Participant has had a major organ transplant (e.g., bone marrow or liver).
  • Participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (e.g., for magnetic resonance imaging).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Open label (OL) venglustat

    Administered once a day orally for up to approximately 10 years. Participants will continue their usual dose of Cerezyme during Part 1, Part 2 and Part 3. There is no administration of Cerezyme in Part 4 unless administrated as rescue treatment.

    Drug: venglustat (GZ402671) · Drug: imiglucerase

Interventions

  • Pharmaceutical form: capsule or tablet Route of administration: oral

  • Pharmaceutical form: sterile lyophilized product Route of administration: intravenous

    Also known as: Cerezyme

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: From screening up to end of study, up to approximately 10 years

  2. Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in cerebrospinal fluid (CSF)

    Time frame: From screening through Week 52

Secondary outcomes

  1. Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in plasma

    Change from baseline in plasma lyso-GL1 and GL1

    Time frame: From screening up to end of study, up to approximately 10 years

  2. Assessment of plasma pharmacokinetic parameter: Cmax (Part 2)

    Plasma maximum concentration (Cmax)

    Time frame: Day 1

  3. Assessment of plasma pharmacokinetic parameter: Tmax (Part 2)

    Plasma time at Cmax (Tmax)

    Time frame: Day 1

  4. Assessment of plasma pharmacokinetic parameter: AUC0-24h (Part 2)

    Plasma area under the curve (AUC0-24h)

    Time frame: Day 1

  5. Assessment of plasma pharmacokinetic parameter: Ctrough

    Plasma trough concentration (Ctrough)

    Time frame: Weeks 12 and 39 (Part 2), and on Weeks 78, 104, and 156 (for Part 3)

  6. Assessment of CSF pharmacokinetic parameter: Cmax

    CSF maximum concentration (Cmax)

    Time frame: Week 4, Week 26, and Week 52

  7. Assessment of spleen volume

    Percent change from baseline in spleen volume assessed by Magnetic Resonance Imaging (MRI)

    Time frame: From screening up to end of study, up to approximately 10 years

  8. Assessment of spleen volume (Part 4)

    Percent change from Part 4 baseline in spleen volume assessed by MRI

    Time frame: From Week 260 up to end of study, up to approximately 10 years

  9. Assessment of liver volume

    Percent change from baseline in liver volume assessed by MRI

    Time frame: From screening up to end of study, up to approximately 10 years

  10. Assessment of liver volume (Part 4)

    Percent change from Part 4 baseline in liver volume assessed by MRI

    Time frame: From Week 260 up to end of study, up to approximately 10 years

  11. Assessment of hemoglobin level

    Change from baseline in hemoglobin level

    Time frame: From screening up to end of study, up to approximately 10 years

  12. Assessment of hemoglobin level (Part 4)

    Change from Part 4 baseline in hemoglobin level

    Time frame: From Week 260 up to end of study, up to approximately 10 years

  13. Assessment of platelet level

    Percent change from baseline in platelet count

    Time frame: From screening up to end of study, up to approximately 10 years

  14. Assessment of platelet level (Part 4)

    Percent change from Part 4 baseline in platelet count

    Time frame: From Week 260 up to end of study, up to approximately 10 years

  15. Assessment of Ataxia

    Ataxia is assessed by using the Scale for the Assessment and Rating of Ataxia (SARA), which consists of 8 items that are related to gait, stance, sitting, speech disturbance, finger-chase test, nose-finger test, fast alternating hand movements and heel-shin slide test. A modified scoring algorithm is used to determine the SARA modified total score from 0 (no ataxia) to 32 (very severe ataxia). Change from baseline in SARA modified total score.

    Time frame: From screening up to end of study, up to approximately 10 years

  16. Assessment of Ataxia (Part 4)

    Ataxia is assessed by using the Scale for the Assessment and Rating of Ataxia (SARA), which consists of 8 items that are related to gait, stance, sitting, speech disturbance, finger-chase test, nose-finger test, fast alternating hand movements and heel-shin slide test. A modified scoring algorithm is used to determine the SARA modified total score from 0 (no ataxia) to 32 (very severe ataxia). Change from Part 4 baseline in SARA modified total score.

    Time frame: From Week 260 up to end of study, up to approximately 10 years

07

Study locations

7 sites
  • Yale University School of Medicine Site Number : 840002
    New Haven, Connecticut 06520, United States
  • Baylor Institute of Metabolic Diseases Site Number : 840001
    Dallas, Texas 75226, United States
  • Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 840003
    Fairfax, Virginia 22030, United States
  • Investigational Site Number : 276001
    Mainz, 55131, Germany
  • Investigational Site Number : 392001
    Minato-ku, Tokyo 105-8471, Japan
  • Investigational Site Number : 826003
    Cambridge, Cambridgeshire CB2 OQQ, United Kingdom
  • Investigational Site Number : 826002
    Salford, Manchester M6 8HD, United Kingdom
08

References and documents

Publications

  • Schiffmann R, Mengel E, Wallace M, Rochmann C, Turnbull J, Krupnick R, Gwaltney C, Pulikottil-Jacob R, Batsu I, Zheng R, Hamed A. Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP). Adv Ther. 2024 Jul;41(7):2907-2923. doi: 10.1007/s12325-024-02881-2. Epub 2024 May 27. PubMed 38802634 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2017 (actual). Primary completion is estimated for Oct 2026, 117 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Jul 25, 2016
StartActual
Jan 4, 2017
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02843035
Responsible party
Sponsor
First posted
Jul 25, 2016
Start date
Jan 4, 2017
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Jul 10, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion